NanoViricides volatility expected to move, FDA 'stands ready' to work on Ebola NanoViricides volatility expected to move as the FDA said it “stands ready” to work with companies and investigators working with patients in “dire need of treatment” for the Ebola virus, Reuters says. Overall option implied volatility of 64 compares to its 26-week average of 79 according to Track Data, suggesting decreasing price movement.
NanoViricides signs agreement with University of Wisconsin NanoViricides announced that it has entered into an agreement with the University of Wisconsin for the evaluation of its nanoviricides drug candidates in models of ocular herpes virus infections. The studies will be performed in the laboratory of Dr. Curtis Brandt, an expert in herpes simplex virus infections and in evaluating anti-viral agents. The Company has previously reported the successes of its nanoviricides drug candidates in pre-clinical studies of dermal herpes virus infections in mouse models. The studies in Dr. Brandt's laboratory will be critical in optimizing its anti-herpes drug candidates against ocular herpes virus infections. The goal of these studies will be to identify a drug development candidate as a treatment for ocular keratitis in humans caused by herpes simplex virus infections.